Nasdaq files Form 25 for TC BioPharm ADS & Warrants

Rhea-AI Filing Summary

What happened: Nasdaq has filed a Form 25 to remove a class of TC BioPharm (Holdings) plc securities from Nasdaq listing and/or registration.

Who and when: The filing names the issuer as TC BioPharm (Holdings) plc and is signed by a Nasdaq hearings advisor on 2025-08-08. The affected classes are the American Depositary Shares and Warrants.

Positive

• None.

Negative

• Nasdaq filed Form 25 to strike a class of securities from listing and/or registration
• Affected securities: American Depositary Shares and Warrants for TC BioPharm (Holdings) plc
• Filing signed by Nasdaq representative (Hearings Advisor Aravind Menon) on 2025-08-08

Insights

Corporate Governance Expert

TL;DR: Nasdaq filed to strike TC BioPharm's ADS and warrants from listing, a material change to the company's market access.

The Form 25 is a formal notice that Nasdaq intends to remove the specified classes of TC BioPharm (Holdings) plc securities from listing and/or registration. The document identifies the affected classes as American Depositary Shares and Warrants and is signed by a Nasdaq hearings advisor on 2025-08-08. For investors, this filing signals a formal delisting action has been initiated at the exchange level; the filing itself does not include financial details, reasons for the removal, or further procedural dates.

Securities Analyst

TL;DR: The exchange submitted Form 25 for TCBPW ADS and warrants, formally starting removal from Nasdaq listing/registration.

The submission of Form 25 by Nasdaq confirms the exchange's certification that it has grounds to strike the listed class of securities. The filing lists the issuer as TC BioPharm (Holdings) plc and specifies American Depositary Shares and Warrants as the affected securities. The form includes regulatory compliance statements but does not indicate sale volumes, market capitalization, or investor remediation steps in this document. The signature date on the filing is 2025-08-08.

UNITED STATES

OMB APPROVAL

OMB Number:			3235-0080
Expires:	March 31, 2018
Estimated average burden
hours per response:			1.7

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 25

NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION
UNDER SECTION 12(b) OF THE SECURITIES EXCHANGE ACT OF 1934.

Commission File Number

333-260492

Issuer:	TC BioPharm (Holdings) plc
Exchange:	Nasdaq Stock Market LLC

(Exact name of Issuer as specified in its charter, and name of Exchange where security is listed and/or registered)

Address:	2 Parklands Way
	Motherwell
	Lanarkshire	UNITED KINGDOM	ML1 4WR
Telephone number:					+44 7936 918476

(Address, including zip code, and telephone number, including area code, of Issuer's principal executive offices)

American Depositary Shares, Warrant

(Description of class of securities)

Please place an X in the box to designate the rule provision relied upon to strike the class of securities from listing and registration:

17 CFR 240.12d2-2(a)(1)

17 CFR 240.12d2-2(a)(2)

17 CFR 240.12d2-2(a)(3)

17 CFR 240.12d2-2(a)(4)

Pursuant to 17 CFR 240.12d2-2(b), the Exchange has complied with its rules to strike the class of securities from listing and/or withdraw registration on the Exchange. ¹

Pursuant to 17 CFR 240.12d2-2(c), the Issuer has complied with its rules of the Exchange and the requirements of 17 CFR 240.12d-2(c) governing the voluntary withdrawal of the class of securities from listing and registration on the Exchange.

Pursuant to the requirements fo the Securities Exchange Act of 1934, Nasdaq Stock Market LLC certifies that it has reasonable grounds to believe that it meets all of the requirements for filing the Form 25 and has caused this notification to be signed on its behalf by the undersigned duly authorized person.

2025-08-08	By	Aravind Menon		Hearings Advisor
Date		Name		Title

¹ Form 25 and attached Notice will be considered compliance with the provisions of 17 CFR 240.19d-1 as applicable. See General Instructions.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did the Form 25 filed for TC BioPharm (TCBPW) state?

The filing states that Nasdaq submitted a Form 25 to remove a class of TC BioPharm (Holdings) plc securities from listing and/or registration, naming American Depositary Shares and Warrants as the affected classes.

Which securities of TCBPW are affected by this filing?

The Form 25 lists the affected classes as American Depositary Shares and Warrants of TC BioPharm (Holdings) plc.

Who filed and when was the Form 25 signed?

The form is certified by Nasdaq Stock Market LLC and is signed by Hearings Advisor Aravind Menon on 2025-08-08.

Does the filing say whether the withdrawal was voluntary or exchange-initiated?

The form includes regulatory compliance statements referencing both the exchange's and the issuer's compliance, but it does not clearly indicate in the filing text which specific rule provision was relied upon to effect the removal.

Where is the issuer located according to the filing?

The filing lists the issuer's principal office address as 2 Parklands Way, Motherwell, Lanarkshire, UNITED KINGDOM ML1 4WR and provides a telephone number.